Olema Shares Plunge 24% After Roche Study Fails PFS Endpoint
Olema Pharmaceuticals’ shares dropped 24% following Roche’s phase 3 persevERA breast cancer study missing its progression-free survival endpoint, raising concerns for Olema’s Palazestrant CERAN/SERD candidate. The company retains collaborations with Pfizer and Novartis and carries a projected 69% upside, while market capitalization stands at $1.28 billion.
1. Roche Phase 3 PersevERA Failure
Roche’s phase 3 PersevERA breast cancer trial failed to achieve a statistically significant improvement in progression-free survival, triggering a sharp decline in Olema Pharmaceuticals’ stock as investors reassess prospects for similar SERD/CERAN therapies.
2. Concerns for Palazestrant Development
The trial setback casts doubt on clinical differentiation of Palazestrant, Olema’s lead complete estrogen receptor antagonist and selective estrogen receptor degrader candidate, potentially delaying regulatory submissions and partner collaborations.
3. Strategic Collaborations Sustain Pipeline
Despite the trial news, Olema maintains research partnerships with Pfizer and Novartis to advance Palazestrant and other targeted women’s cancer therapies, underscoring ongoing industry support for its pipeline.
4. Trading Volatility and Market Profile
Shares traded as low as $12.99 and high as $18.62 in intraday moves, reflecting significant volatility; over the past year, the stock ranged between $2.86 and $36.26, with market capitalization near $1.28 billion and daily volume around 11.9 million shares.